InvestorsObserver is giving Lantern Pharma Inc (LTRN) an Analyst Rating Rank of 5, meaning LTRN is ranked higher by analysts than 5% of stocks. The average price target for LTRN is $26 and analyst’s rate the stock as a Hold.
Wall Street analysts are rating LTRN a Hold today. Find out what this means to you and get the rest of the rankings on LTRN!